• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.

作者信息

De Servi Stefano, Landi Antonio, Savonitto Stefano

机构信息

University of Pavia Medical School, 27100, Pavia, Italy.

IRCCS MultiMedica, Sesto San Giovanni, 20099, Milan, Italy.

出版信息

Cardiovasc Drugs Ther. 2021 Apr;35(2):399-401. doi: 10.1007/s10557-020-07055-0. Epub 2020 Aug 18.

DOI:10.1007/s10557-020-07055-0
PMID:32809109
Abstract
摘要

相似文献

1
Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.老年急性冠状动脉综合征患者的抗血小板治疗：氯吡格雷的逆袭：强势回归的可能原因
Cardiovasc Drugs Ther. 2021 Apr;35(2):399-401. doi: 10.1007/s10557-020-07055-0. Epub 2020 Aug 18.
2
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].[ISAR-REACT 5试验：在急性冠状动脉综合征中，普拉格雷和替格瑞洛谁更胜一筹？]
G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764.
3
Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation.支架植入治疗的急性冠状动脉综合征患者双联抗血小板治疗中断及P2Y12抑制剂转换的频率和原因
Cardiology. 2019;142(4):203-207. doi: 10.1159/000500977. Epub 2019 Jul 2.
4
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.双联抗血小板治疗中使用普拉格雷或替格瑞洛的 P2Y12 抑制剂致眼内出血的荟萃分析。
Am J Cardiol. 2020 Apr 15;125(8):1280-1283. doi: 10.1016/j.amjcard.2020.01.012. Epub 2020 Jan 29.
5
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.替格瑞洛、普拉格雷或氯吡格雷对血管内皮功能和其他血管生物标志物的影响：一项随机交叉研究。
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022. Epub 2018 May 24.
6
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.替格瑞洛或普拉格雷与氯吡格雷三联抗血小板治疗联合糖蛋白 IIb/IIIa 抑制剂用于接受 PCI 的 STEMI 患者：一项荟萃分析。
BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6.
7
Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.血小板补充对血小板 P2Y12 抑制的逆转作用：普拉格雷、氯吡格雷和替格瑞洛的离体和体外比较。
J Thromb Haemost. 2018 Jun;16(6):1089-1098. doi: 10.1111/jth.14014. Epub 2018 Apr 23.
8
Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.急性冠状动脉综合征伴不良临床结局患者经皮冠状动脉介入治疗中静脉桥病变的抗血小板药物选择：来自英国心血管介入学会数据库的分析。
Catheter Cardiovasc Interv. 2018 Oct 1;92(4):659-665. doi: 10.1002/ccd.27493. Epub 2018 Jan 22.
9
Duration of Dual Antiplatelet Therapy in the Post-Acute Coronary Syndrome Patient.急性冠状动脉综合征患者双联抗血小板治疗的持续时间。
J Cardiovasc Nurs. 2018 May/Jun;33(3):248-254. doi: 10.1097/JCN.0000000000000452.
10
Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy?普拉格雷和替格瑞洛：抗血小板治疗中的罗慕路斯和雷穆斯？
Am J Cardiovasc Drugs. 2019 Aug;19(4):377-379. doi: 10.1007/s40256-019-00340-w.

引用本文的文献

1
Treatment of non-ST-segment elevation myocardial infarction in the elderly: the SENIOR-RITA trial.老年非ST段抬高型心肌梗死的治疗：SENIOR-RITA试验
Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii131-iii136. doi: 10.1093/eurheartjsupp/suaf031. eCollection 2025 Mar.
2
Clopidogrel: Drug of the Past or Drug of the Future?氯吡格雷：过去的药物还是未来的药物？
Cardiovasc Drugs Ther. 2024 Dec;38(6):1073-1076. doi: 10.1007/s10557-024-07629-2. Epub 2024 Sep 9.
3
A new goal for secondary prevention of cardiovascular diseases: the reduction of neutrophil count.
心血管疾病二级预防的新目标：降低中性粒细胞计数。
Future Cardiol. 2024;20(10):517-519. doi: 10.1080/14796678.2024.2384239. Epub 2024 Aug 7.
4
Antiplatelet therapy in elderly patients with ACS: moving targets need more tailored treatments.老年急性冠状动脉综合征患者的抗血小板治疗：不断变化的目标需要更具针对性的治疗。
J Thromb Thrombolysis. 2024 Mar;57(3):358-360. doi: 10.1007/s11239-023-02942-3. Epub 2024 Jan 28.
5
Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field.老年急性冠状动脉综合征患者的抗血小板策略：在低证据领域中寻找方向
J Clin Med. 2023 Mar 6;12(5):2082. doi: 10.3390/jcm12052082.